Sterigenics Germany GmbH primarily provides sterilization services for medical articles as well as related validation services and additional laboratory services. The company belongs to the global Sterigenics business unit of the Sotera Health Group; Sotera Health Company has been listed on NASDAQ since March 2021. Its customers are essentially international manufacturers of medical products. In the European market there are few international competitors for large-volume sterilization while numerous medium-sized and small competitors serve smaller batch sizes. The company does not maintain its own research and development department; technical developments are sourced externally and implemented internally.
die Durchführung von mikrobiologischen, chemischen und physikalischen Laborversuchen und die Forschung auf diesem Gebiet, die Sterilisation von Produkten, die Herstellung von damit im Zusammenhang stehenden Produkten und der Handel damit.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Wiesbaden Local Court, HRB 22418 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Knut Alfs | Geschäftsführer(in) | Guntersblum |
Source: German Commercial Register (Handelsregister) Wiesbaden Local Court, HRB 22418 (as of 30 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 19.12.2012 | Business Address Change | Kasteler Straße 45, 65203 Wiesbaden |
| 07.07.2010 | Registered Seat Change | eingetragen als |
| 07.07.2010 | Business Address Registered | Rheingaustraße 190-196, 65203 Wiesbaden |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 29.05.2006 | Share Capital Set | — | 250.000 DM |
Source: German Commercial Register (Handelsregister) Wiesbaden Local Court, HRB 22418 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€26.1M2 | €4,012,171 | €35,493,275 | 107 |
| 2023 | Rohergebnis€25M2 | €3,494,956 | €30,700,842 | 104 |
| 2022 | Rohergebnis€22.4M2 | €3,434,730 | €27,724,616 | 91 |
| 2021 | Rohergebnis€21.2M2 | €3,986,707 | €23,964,822 | 92 |
| 2020 | Rohergebnis€18.9M2 | €3,300,910 | €19,825,005 | 86 |
| 2019 | Rohergebnis€17M2 | €2,755,358 | €15,578,991 | 83 |
| 2018 | Rohergebnis€14.7M2 | €1,630,191 | €15,306,199 | 76 |
| 2017 | Rohergebnis€12.6M2 | €591,965 | €16,805,965 | 73 |
| 2016 | Rohergebnis€12.4M2 | €2,172,642 | €10,324,226 | 66 |
| 2015 | Rohergebnis€11.9M2 | €2,129,677 | €9,314,329 | 65 |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Wiesbaden Local Court, HRB 22418 (as of 30 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €7,567,577 | 81.7% |
| Depreciation | €1,673,676 | 18.1% |
| Interest & Similar | €15,727 | 0.2% |
